SMAD family member 1Genealiases: BSP-1 · BSP1 · JV4-1 · JV41 · MADH1 · MADR1
Q-omics provides the consensus-scored SMAD1 profile across patient tissues and cancer cell-line models. SMAD1 expression is associated with patient survival in 24 of 34 cancer types, with the highest sampling consensus in HNSC. Among the 18 cancer types available for tumor–normal comparison, SMAD1 is differentially expressed in 9, with the highest sampling consensus in THCA. Additionally, SMAD1 RNA expression shows 20,344 significant gene co-expression associations, with the highest sampling consensus in ACC. Together, these results highlight HNSC, THCA, and ACC as cancer lineages where SMAD1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for SMAD1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes SMAD1 survival associations across molecular data types. SMAD1 RNA expression shows survival associations in the most cancer types (24), followed by mutation status (2) and mass-spec protein abundance (6). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible SMAD1 RNA expression–survival associations across cancer types. High SMAD1 expression shows unfavorable associations in MESO and THCA, but favorable associations in HNSC, KIRC, UCS and BRCA. The HNSC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify HNSC as the clearest survival context for SMAD1 RNA expression.
This table summarizes SMAD1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 9, while mass-spec protein shows differences in 5. The strongest signals are observed in THCA for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for SMAD1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. SMAD1 shows lower tumor expression in THCA, KIRC and COAD and higher tumor expression in HNSC, LUSC and LUAD. The THCA box plot shows higher SMAD1 RNA expression in normal versus tumor tissue (log2 FC = −1.298, t-test p < 0.001).
This table shows molecular features associated with SMAD1 in patient tissues and cancer cell lines. In patient samples, SMAD1 shows the broadest associations at the RNA and protein expression levels, with ACC recurring as the lineage with the largest associated feature set. In cancer cell lines, SMAD1 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LARGE_INTESTINE, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Lymphoma and BLOOD_Leukemia.
